每日与小儿性综合征的交替日莱瓦米索尔相比:一项开放式随机对照研究
Sushmita Banerjee1, Jayati Sengupta2, Rajiv Sinha2
1Department of Nephrology, Institute of Child Health, Kolkata, India. asban444@gmail.com.
Pediatric nephrology (Berlin, Germany)
|May 31, 2024
概括
在患有性综合征的儿童中,每日素治疗并没有改善持续缓解率. 然而,它显著降低了复发率和类固醇剂量,而与交替日剂量相比,它没有增加不良反应.
科学领域:
- 儿科脏病学 儿科脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 莱瓦米索尔为脏病综合征的其他类固醇节约剂提供了具有成本效益和安全性的替代品.
- 传统的交替日米索尔的使用与其相对较短的血半衰期形成鲜明对比.
- 儿童经常复发或类固醇依赖性性综合征 (FR/SDNS) 往往需要优化治疗策略.
研究的目的:
- 评估每日米索尔与每日米索尔在维持儿科FR/SDNS的缓解中的安全性和有效性.
- 为了比较两个莱瓦米索尔注射计划之间的持续缓解率,复发频率和类固醇需求.
主要方法:
- 一个开放的随机对照试验,涉及190名患有FR/SDNS的儿童.
- 组A每天接受牛醇;组B接受了12个月的交替日牛醇,与3个月的普雷迪尼索隆逐渐减少.
- 评估结果包括持续缓解,复发率,类固醇剂量和不良反应.
主要成果:
- 持续缓解率相似 (36%的每日缓解率与27%的每日缓解率相似;p=0.18).
- 每日使用莱瓦米索尔显著降低了复发率 (p=0.03) 和累积类固醇剂量 (p=0.02).
- 两组之间的不良反应是可比的,可逆性白血病和肝透氨酸炎是最常见的.
结论:
- 每日米索尔的效果并不优于每隔一天的剂量,可以在12个月内在儿科FR/SDNS中实现持续缓解.
- 每日服用可降低复发率和降低类固醇需求,而不会损害安全性,从而带来显著的益处.
- 进一步的研究可能会探索莱瓦米索尔在管理FR/SDNS时的最佳剂量策略.
更多相关视频
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
2.9K
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.1K
相关概念视频
01:01Dosage Regimen: Fixed Dose
1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
159
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
159